New mRNA vaccine targets RSV in first human trial
NCT ID NCT06645665
First seen Apr 04, 2026 · Last updated May 24, 2026 · Updated 7 times
Summary
This early-stage study tests a new mRNA vaccine (IN006) designed to protect against respiratory syncytial virus (RSV). About 240 healthy adults aged 18 and older will receive one of three vaccine doses or a placebo. Researchers will monitor side effects and measure immune responses, including a booster shot given one year later to older adults (60+).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Anning First People's Hospital
Kunming, Yunnan, China
-
Huashan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.